General Surgery Coding Alert - 2004 Issue 22
OIG Targets Drug Payments
Subscribe or sign in to view the full article.
Article Overview
This article covers an HHS Office of Inspector General semiannual report to Congress and focuses on federal oversight of drug payments and pharmaceutical pricing. It discusses recovery activity, investigations into pricing and compliance issues, and monitoring efforts tied to Medicare and drug pricing policy. The piece is relevant to compliance teams, health care administrators, pharmacy stakeholders, and anyone tracking federal audit and reimbursement oversight.
Why This Topic Matters
It highlights government scrutiny of drug pricing and payment practices, which can affect compliance planning, reimbursement monitoring, and audit risk for organizations involved in pharmaceutical billing or Medicare-related services.
What You Will Learn
- How the HHS Office of Inspector General characterizes its recent recovery and oversight activity
- What broad pharmaceutical pricing and compliance issues are being examined
- Why Medicare-related drug payment monitoring is receiving additional attention
- How federal oversight developments may affect health care stakeholders
Who Should Read This
- Health care compliance professionals
- Pharmacy and pharmaceutical stakeholders
- Hospital and provider revenue cycle teams
- Medicare administrators and policy analysts
- Medical coding and billing professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com